PIPAC systems from Reger
Füge hier deinen Tooltip-Text hinzu
Füge hier deinen Tooltip-Text hinzu
Füge hier deinen Tooltip-Text hinzu
Füge hier deinen Tooltip-Text hinzu
Füge hier deinen Tooltip-Text hinzu
Innovative medical technology for intraperitoneal chemotherapy
The treatment of peritoneal metastases poses complex challenges for clinics: systemic chemotherapy often fails to achieve the required depth of effect due to limited blood flow to the peritoneum, while extensive surgery is associated with high stress levels.
PIPAC – Pressurized IntraPeritoneal Aerosol Chemotherapy – offers a new approach.
In this minimally invasive procedure, chemotherapy is administered directly into the abdominal cavity as a pressurized aerosol. This enables better intraperitoneal penetration of the active substance while reducing systemic stress.
A modern option for peritoneal cancer.
PIPAC therapy is performed as part of a minimally invasive laparoscopy during a laparoscopy. The CO₂ pressure ensures that the active substance mist is distributed evenly and droplets penetrate the tumor surface. The therapy can be repeated and is often part of a multimodal treatment concept.
Key advantages of the method:
- Locally high concentration of active ingredients
- Potentially fewer side effects than systemic chemotherapy
- Standardized, reproducible surgical procedures
- Suitable for multiple consecutive applications
Technological pioneer with over a decade of experience
REGER has been involved in the technical development of PIPAC systems since their first clinical applications. Continuous research and technical optimization have resulted in nebulization systems that are specifically tailored to the requirements of intraperitoneal PIPAC.
Our claim:
- Precise and reproducible aerosol formation
- Constant and controllable pressure conditions
- Homogeneous distribution in the abdominal cavity
- Highest safety standards in accordance with MDR Class IIb
REGER systems—including QuattroJet® technology—are currently used in specialized PIPAC centers worldwide and comply with the latest regulatory standards for medical technology.
- 1975 – Founding of REGER
- 2009 – Development of the first Nebulizer
- 2012 – Start of sales of Nebulizer
- 2015 – Manufacturer of CapnoPen until 2022
- 2015 – Capnomed: Exklusive Distributor of REGER
- 2022 – MDR Certification of REGER
- 2023 – 510(k) Clearance
- 2025 – MDR Certification Class Ilb
- 2025 – Development and Marketing of PowerInjector
The benchmark in PIPAC development
Reger stands for progress in PIPAC technology like no other name. Extensive studies confirm the clinical value of the procedure and reflect the intensive development work that has gone into it. With its deep understanding of the process and continuous innovation, Reger maintains its position as a leading developer and driving force in the field of PIPAC.
Why REGER systems?
Our technology supports the safe, reproducible, and efficient implementation of PIPAC therapy:
- MDR-compliant medical devices (Class IIb)
- Robust construction and reliable components
- Optimized aerosol characteristics
- Products "Made in Germany"
- Technical support and training available
For distributors and sales partners of medical technology
REGER offers distribution partners a growing market segment with technologically mature, clinically established products. Our PIPAC systems stand for certified safety, resilient supply chains, and high-quality medical documentation.
For healthcare professionals and clinics
Learn more about the technology, read experienced user reports, find out about workflow integration, training opportunities, and technical details on nebulizers and accessories.
For patients and their families
PIPAC therapy is only performed in specialized centers. Here you will find guidance and information about the German PIPAC center.
Your contact for all matters relating to the REGER system
Für Fragen zu Produkten, technischen Details oder zur Integration in Ihre Klinikprozesse steht Ihnen unser Ansprechpartner gerne persönlich zur Verfügung.
Daniel Seemann
Sales Manager
E-Mail: d.seemann@reger-med.de
Phone: +49 176 4332 8487